Clinical study of lamivudine treatment on patients with dencompensated cirrhosis post hepatitis

OBJECTIVE To observe the efficiency and safety of long-term lamivudine used in dencompensated cirrhosis following chronic hepatitis B.METHODS 31 patients with dencompensated cirrhosis were divided randomly into two grops:sixteen patients with dencompensated cirrhosis received lamivudine 100mg daily for period 24~54 months.The changes were observed and detectived before lamivudine treatment,and compared with lamivudine treatment including clinical status,ALT,AST,Ab,Tbil,PT and HBVDNA levels,child-pugh score,and compared with the control group without lamivudine treatment for period 24~52 months. RESULTS After the treatment of lamivudine,there were fourteen patients whose clinical symptoms,signs and liver function(include ALT,AST,Ab,Tbil and PT) improved(P0.01),and HBVDNA levels decreased at least 10~(3) copies/ml(P0.01),child-pugh score declined(P0.01),except two patients died with complications.In the control group,nine patients didn't improve in clinical status and liver function(P0.05),except six patients died with complications.CONCLUSION Long-term lamivudine treatment on dencompensated cirrhosis following chronic hepatitis B could decrease drastically HBVDNA levels,prevent hepatocellular from damage,it is an significantly effective and safty drug that improved liver function and life quality.